p300 protein acetyltransferase activity suppresses systemic lupus erythematosus-like autoimmune disease in mice

Journal of Immunology

Volumn 178, Issue 11, 2007, Pages 6941-6948

  Forster, Nicole ^a   Gallinat, Sven ^a   Jablonska, Jadwiga ^b   Weiss, Siegfried ^b   Elsasser, Hans Peter ^a   Lutz, Werner ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; AUTOANTIBODY; B LYMPHOCYTE RECEPTOR; DOUBLE STRANDED DNA ANTIBODY; HISTONE ACETYLTRANSFERASE; IMMUNOGLOBULIN G2B; PROTEIN P300;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIGEN ANTIBODY COMPLEX; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CLINICAL FEATURE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME REPRESSION; GLOMERULONEPHRITIS; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PENETRANCE; PRIORITY JOURNAL; RECEPTOR UPREGULATION; SPLENOMEGALY; STIMULUS RESPONSE; SYSTEMIC LUPUS ERYTHEMATOSUS; VASCULITIS;

EID: 34249802618     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.178.11.6941     Document Type: Article

References (57)

1. Carrozza, M. J., R. T. Utley, J. L. Workman, and J. Cote. 2003. The diverse functions of histone acetyltransferase complexes. Trends Genet. 19: 321-329.
2. Redner, R. L., J. Wang, and J. M. Liu. 1999. Chromatin remodeling and leukemia: new therapeutic paradigms. Blood 94: 417-428.
3. Minucci, S., and P. G. Pelicci. 2006. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 6: 38-51.
4. Roth, S. Y., J. M. Denu, and C. D. Allis. 2001. Histone acetyltransferases. Annu. Rev. Biochem. 70: 81-120.
5. Ogryzko, V. V., R. L. Schiltz, V. Russanova, B. H. Howard, and Y. Nakatani. 1996. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 87: 953-959.
6. Goodman, R. H., and S. Smolik. 2000. CBP/p300 in cell growth, transformation, and development. Genes Dev. 14: 1553-1577.
7. Chan, H. M., and N. B. La Thangue. 2001. p300/CBP proteins: HATs for transcriptional bridges and scaffolds. J. Cell Sci. 114: 2363-2373.
8. Bereshchenko, O. R., W. Gu, and R. Dalla-Favera. 2002. Acetylation inactivates the transcriptional repressor BCL6. Nat. Genet. 32: 606-613.
9. Chen, L. F., Y. Mu, and W. C. Greene. 2002. Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-KB. EMBO J. 21: 6539-6548.
10. Blobel, G. A. 2000. CREB-binding protein and p300: molecular integrators of hematopoietic transcription. Blood 95: 745-755.
11. Grossman, S. R., M. E. Deato, C. Brignone, H. M. Chan, A. L. Kung, H. Tagami, Y. Nakatani, and D. M. Livingston. 2003. Polyubiquitination of p53 by a ubiquitin ligase activity of p300. Science 300: 342-344.
12. Girdwood, D., D. Bumpass, O. A. Vaughan, A. Thain, L. A. Anderson, A. W. Snowden, E. Garcia-Wilson, N. D. Perkins, and R. T. Hay. 2003. P300 transcriptional repression is mediated by SUMO modification. Mol. Cell 11: 1043-1054.
13. Agalioti, T., G. Chen, and D. Thanos. 2002. Deciphering the transcriptional histone acetylation code for a human gene. Cell 111: 381-392.
14. Roth, J. F., N. Shikama, C. Henzen, I. Desbaillets, W. Lutz, S. Marino, J. Wittwer, H. Schorle, M. Gassmann, and R. Eckner. 2003. Differential role of p300 and CBP acetyltransferase during myogenesis: p300 acts upstream of MyoD and Myf5. EMBO J. 22: 5186-5196.
15. Shikama, N., W. Lutz, R. Kretzschmar, N. Sauter, J. F. Roth, S. Marino, J. Wittwer, A. Scheidweiler, and R. Eckner. 2003. Essential function of p300 acetyltransferase activity in heart, lung and small intestine formation. EMBO J. 22: 5175-5185.
16. Black, J. C., J. E. Choi, S. R. Lombardo, and M. Carey. 2006. A mechanism for coordinating chromatin modification and preinitiation complex assembly. Mol. Cell 23: 809-818.
17. Rebel, V. I., A. L. Kung, E. A. Tanner, H. Yang, R. T. Bronson, and D. M. Livingston. 2002. Distinct roles for CREB-binding protein and p300 in hematopoietic stem cell self-renewal. Proc. Natl. Acad. Sci. USA 99: 14789-14794.
18. Xu, W., T. Fukuyama, P. A. Ney, D. Wang, J. Rehg, K. Boyd, J. M. van Deursen, and P. K. Brindle. 2006. Global transcriptional coactivators CREB-binding protein and p300 are highly essential collectively but not individually in peripheral B-cells. Blood 107: 4407-4416.
19. Sandberg, M. L., S. E. Sutton, M. T. Pletcher, T. Wiltshire, L. M. Tarantino, J. B. Hogenesch, and M. P. Cooke. 2005. c-Myb and p300 regulate hematopoietic stem cell proliferation and differentiation. Dev. Cell 8: 153-166.
20. Kasper, L. H., F. Boussouar, P. A. Ney, C. W. Jackson, J. Rehg, J. M. van Deursen, and P. K. Brindle. 2002. A transcription-factor-binding surface of coactivator p300 is required for haematopoiesis. Nature 419: 738-743.
21. Rickert, R. C., J. Roes, and K. Rajewsky. 1997. B lymphocyte-specific, Cremediated mutagenesis in mice. Nucleic Acids Res. 25: 1317-1318.
22. Xu, W., T. Fukuyama, P. A. Ney, D. Wang, J. Rehg, K. Boyd, J. M. van Deursen, and P. K. Brindle. 2006. Global transcriptional coactivators CREB-binding protein and p300 are highly essential collectively but not individually in peripheral B cells. Blood 107: 4407-4416.
23. Whitacre, C. C. 2001. Sex differences in autoimmune disease. Nat. Immunol. 2: 777-780.
24. Shlomchik, M. J., J. E. Craft, and M. J. Mamula. 2001. From T to B and back again: positive feedback in systemic autoimmune disease. Nat. Rev. Immunol. 1: 147-153.
25. Edwards, J. C., and G. Cambridge. 2006. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat. Rev. Immunol. 6: 394-403.
26. Jun, J. E., and C. C. Goodnow. 2003. Scaffolding of antigen receptors for immunogenic versus tolerogenic signaling. Nat. Immunol. 4: 1057-1064.
27. Chan, O. T., M. P. Madaio, and M. J. Shlomchik. 1999. B cells are required for lupus nephritis in the polygenic, Fas-intact MRL model of systemic autoimmunity. J. Immunol. 163: 3592-3596.
28. Looney, R. J., J. H. Anolik, D. Campbell, R. E. Felgar, F. Young, L. J. Arend, J. A. Sloand, J. Rosenblatt, and I. Sanz. 2004. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum. 50: 2580-2589.
29. Lund, F. E., B. A. Garvy, T. D. Randall, and D. P. Harris. 2005. Regulatory roles for cytokine-producing B cells in infection and autoimmune disease. Curr. Dir. Autoimmun. 8: 25-54.
30. Knoechel, B., J. Lohr, E. Kahn, and A. K. Abbas. 2005. The link between lymphocyte deficiency and autoimmunity: roles of endogenous T and B lymphocytes in tolerance. J. Immunol. 175: 21-26.
31. Lipsky, P. E. 2001. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat. Immunol. 2: 764-766.
32. Chan, O. T., L. G. Hannum, A. M. Haberman, M. P. Madaio, and M. J. Shlomchik. 1999. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J. Exp. Med. 189: 1639-1648.
33. Waters, S. T., M. McDuffie, H. Bagavant, U. S. Deshmukh, F. Gaskin, C. Jiang, K. S. Tung, and S. M. Fu. 2004. Breaking tolerance to double stranded DNA, nucleosome, and other nuclear antigens is not required for the pathogenesis of lupus glomerulonephritis. J. Exp. Med. 199: 255-264.
34. Goodnow, C. C., J. Sprent, B. Fazekas de St Groth, and C. G. Vinuesa. 2005. Cellular and genetic mechanisms of self tolerance and autoimmunity. Nature 435: 590-597.
35. Bolland, S., and J. V. Ravetch. 2000. Spontaneous autoimmune disease in FcγRIIB-deficient mice results from strain-specific epistasis. Immunity 13: 277-285.
36. Cyster, J. G., J. I. Healy, K. Kishihara, T. W. Mak, M. L. Thomas, and C. C. Goodnow. 1996. Regulation of B-lymphocyte negative and positive selection by tyrosine phosphatase CD45. Nature 381: 325-328.
37. Grimaldi, C. M., R. Hicks, and B. Diamond. 2005. B cell selection and susceptibility to autoimmunity. J. Immunol. 174: 1775-1781.
38. Nishizumi, H., I. Taniuchi, Y. Yamanashi, D. Kitamura, D. Ilic, S. Mori, T. Watanabe, and T. Yamamoto. 1995. Impaired proliferation of peripheral B cells and indication of autoimmune disease in lyn-deticient mice. Immunity 3: 549-560.
39. Garcia-Rodriguez, C., and A. Rao. 1998. Nuclear factor of activated T cells (NFAT)-dependent transactivation regulated by the coactivators p300/CREB-binding protein (CBP). J. Exp. Med. 187: 2031-2036.
40. Zhong, H., R. E. Voll, and S. Ghosh. 1998. Phosphorylation of NF-κB p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300. Mol. Cell 1: 661-671.
41. Simonsson, M., M. Kanduri, E. Gronroos, C. H. Heldin, and J. Ericsson. 2006. The DNA binding activities of Smad2 and Smad3 are regulated by coactivator-mediated acetylation. J. Biol. Chem. 281: 39870-39880.
42. Yaswen, L., A. B. Kulkarni, T. Fredrickson, B. Mitfleman, R. Schiffman, S. Payne, G. Longenecker, E. Mozes, and S. Karlsson. 1996. Autoimmune manifestations in the transforming growth factor-β1 knockout mouse. Blood 87: 1439-1445.
43. Roes, J., B. K. Choi, and B. B. Cazac. 2003. Redirection of B cell responsiveness by transforming growth factor β receptor. Proc. Natl. Acad. Sci. USA 100: 7241-7246.
44. Gingras, S., J. Simard, B. Groner, and E. Pfitzner. 1999. p300/CBP is required for transcriptional induction by interleukin-4 and interacts with Stat6. Nucleic Acids Res. 27: 2722-2729.
45. Wang, J. H., N. Avitahl, A. Cariappa, C. Friedrich, T. Ikeda, A. Renold, K. Andrikopoulos, L. Liang, S. Pillai, B. A. Morgan, and K. Georgopoulos. 1998. Aiolos regulates B cell activation and maturation to effector state. Immunity 9: 543-553.
46. Sun, J., G. Matthias, M. J. Mihatsch, K. Georgopoulos, and P. Matthias. 2003. Lack of the transcriptional coactivator OBF-1 prevents the development of systemic lupus erythematosus-like phenotypes in Aiolos mutant mice. J. Immunol. 170: 1699-1706.
47. Hibbs, M. L., K. W. Harder, J. Armes, N. Kountouri, C. Quilici, F. Casagranda, A. R. Dunn, and D. M. Tarlinton. 2002. Sustained activation of Lyn tyrosine kinase in vivo leads to autoimmunity. J. Exp. Med. 196: 1593-1604.
48. Nguyen, C., N. Limaye, and E. K. Wakeland. 2002. Susceptibility genes in the pathogenesis of murine lupus. Arthritis Res. 4(Suppl. 3): S255-S263.
49. Morel, L., X. H. Tian, B. P. Croker, and E. K. Wakeland. 1999. Epistatic modifiers of autoimmunity in a murine model of lupus nephritis. Immunity II: 131-139.
50. Jacobi, A. M., and B. Diamond. 2005. Balancing diversity and tolerance: lessons from patients with systemic lupus erythematosus. J. Exp. Med. 202: 341-344.
51. Singh, R. R. 2005. SLE: translating lessons from model systems to human disease. Trends Immunol. 26: 572-579.
52. Roelfsema, J. H., S. J. White, Y. Ariyurek, D. Bartholdi, D. Niedrist, F. Papadia, C. A. Bacino, J. T. den Dunnen, G. J. van Ommen, M. H. Breuning, et al. 2005. Genetic heterogeneity in Rubinstein-Taybi syndrome: mutations in both the CBP and EP300 genes cause disease. Am. J. Hum. Genet. 76: 572-580.
53. Murata, T., R. Kurokawa, A. Krones, K. Tatsumi, M. Ishii, T. Taki, M. Masuno, H. Ohashi, M. Yanagisawa, M. G. Rosenfeld, et al. 2001. Defect of histone acetyltransferase activity of the nuclear transcriptional coactivator CBP in Rubinstein-Taybi syndrome. Hum. Mol. Genet. 10: 1071-1076.
54. Reilly, C. M., N. Mishra, J. M. Miller, D. Joshi, P. Ruiz, V. M. Richon, P. A. Marks, and G. S. Gilkeson. 2004. Modulation of renal disease in MRL/lpr mice by suberoylanilide hydroxamic acid. J. Immunol. 173: 4171-4178.
55. Garcia, B. A., S. A. Busby, J. Shabanowitz, D. F. Hunt, and N. Mishra. 2005. Resetting the epigenetic histone code in the MRL-lpr/lpr mouse model of lupus by histone deacetylase inhibition. J. Proteome Res. 4: 2032-2042.
56. Yasuda, K., P. Yu, C. J. Kirschning, B. Schlatter, F. Schmitz, A. Heit, S. Bauer, H. Hochrein, and H. Wagner. 2005. Endosomal translocation of vertebrate DNA activates dendritic cells via TLR9-dependent and -independent pathways. J. Immunol. 174: 6129-6136.
57. Bauer, S., C. J. Kirschning, H. Hacker, V. Redecke, S. Hausmann, S. Akira, H. Wagner, and G. B. Lipford. 2001. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc. Natl. Acad. Sci. USA 98: 9237-9242.